Mobileye to Launch Its Own Robotaxi Service in the U.S. in 2027
The company plans to start with around 100 vehicles and scale to 17,000 within five years.
Already have an account? Sign in.
The company plans to start with around 100 vehicles and scale to 17,000 within five years.
The FDA approved Scholar Rock’s Isembyld, the first SMA therapy aimed at muscle wasting in patients already on nerve-targeted treatment.
The Phase III SERENA-4 trial did not meet its primary PFS endpoint in untreated advanced ER-positive, HER2-negative breast cancer, despite a numerical benefit.
Citi added a 90-day upside view on AppLovin with a $600 target, calling Q3 concerns misguided.